APA (7th ed.) Citation

BC, S., P, K., M, d. L., & AM, J. J. (2025). Measurable residual disease testing and allogeneic hematopoietic cell transplantation for AML: Adapting Pre-MEASURE to clinical practice. Bone marrow transplantation, 60(2), 128. https://doi.org/10.1038/s41409-024-02481-2

Chicago Style (17th ed.) Citation

BC, Shaffer, Kebriaei P, de Lima M, and Jimenez Jimenez AM. "Measurable Residual Disease Testing and Allogeneic Hematopoietic Cell Transplantation for AML: Adapting Pre-MEASURE to Clinical Practice." Bone Marrow Transplantation 60, no. 2 (2025): 128. https://doi.org/10.1038/s41409-024-02481-2.

MLA (9th ed.) Citation

BC, Shaffer, et al. "Measurable Residual Disease Testing and Allogeneic Hematopoietic Cell Transplantation for AML: Adapting Pre-MEASURE to Clinical Practice." Bone Marrow Transplantation, vol. 60, no. 2, 2025, p. 128, https://doi.org/10.1038/s41409-024-02481-2.